Hormonal Contraceptive Use on Factor V Leiden Gene Possessing Females and the Risk of Deep Vein Thrombosis — Presentation Detail — Celebration of Scholars

Instructions

Student presentations must have a faculty sponsor.

Abstracts must include a title and a description of the research, scholarship, or creative work. The description should be 150-225 words in length and constructed in a format or style appropriate for the presenter’s discipline.

The following points should be addressed within the selected format or style for the abstract:

A clear statement of the problem or question you pursued, or the scholarly goal or creative theme achieved in your work.
A brief comment about the significance or uniqueness of the work.
A clear description of the methods used to achieve the purpose or goals for the work.
A statement of the conclusions, results, outcomes, or recommendations, or if the work is still in progress, the results you expect to report at the event.

Presenter photographs should be head and shoulder shots comparable to passport photos.

Additional Information

More information is available at carthage.edu/celebration-scholars/. The following are members of the Research, Scholarship, and Creativity Committee who are eager to listen to ideas and answer questions:

Jun Wang
Kim Instenes
John Kirk
Nora Nickels
Andrew Pustina
James Ripley

Hormonal Contraceptive Use on Factor V Leiden Gene Possessing Females and the Risk of Deep Vein Thrombosis

Name: Tabitha Long
Major: Athletic Training
Hometown: Kingston
Faculty Sponsor: Laurie Jensen
Other Sponsors:
Type of research: Course project

Abstract

Abstract

Background: The use of hormonal contraceptives (HC) causes an increased risk of venous thrombosis (VT). When paired with a diagnosis of Factor V Leiden (FVL), there may be an increased risk of venous thrombosis.

Method: After reading a compilation of clinical trials and case studies from a variation of scholarly sources such as pubmed and the American Heart Association, the information was gathered to examine the correlation of the population who takes HC and has a medical history of FVL. Terms including Factor V Leiden, birth control, hormonal birth control, DVT, and Deep vein thrombosis risk were used to search for the articles. Many articles had some information, but very few were actually able to be used for solid research. As a result, five articles were obtained for this research project.

Results: For the FVL mutation carrying population, taking a HC with a possibility of VT is at a slightly increased risk.

Conclusion: Due to the anticoagulant effect from the resistance against protein C in people with a medical diagnosis of FVL, there is a slightly increased risk of VT for those people who also use HC.